- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07223203
TRITON-PN: 다발신경병증이 동반된 유전성 트랜스티레틴 아밀로이드증 환자에서 누크레시란의 효능과 안전성을 평가하는 연구 (TRITON-PN)
TRITON-PN: 유전성 트랜스티레틴 매개 아밀로이드증과 다발신경병증(hATTR-PN) 환자를 대상으로 누크레시란의 효능과 안전성을 평가하기 위한 3상, 글로벌, 무작위, 개방형 연구
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trial Information Line
- 전화번호: 1-877-ALNYLAM
- 이메일: clinicaltrials@alnylam.com
연구 연락처 백업
- 이름: Clinical Trial Information Line
- 전화번호: 1-877-256-9526
- 이메일: clinicaltrials@alnylam.com
연구 장소
-
-
-
Athens, 그리스, 115 28
- 모병
- Clinical Trial Site
-
Heraklion, 그리스, 715 00
- 모병
- Clinical Trial Site
-
-
-
-
-
Taipei, 대만, 10002
- 모병
- Clinical Trial Site
-
Taipei, 대만, 112
- 모병
- Clinical Trial Site
-
Taoyuan City, 대만, 33305
- 모병
- Clinical Trial Site
-
-
-
-
-
Seoul, 대한민국, 06351
- 모병
- Clinical Trial Site
-
Seoul, 대한민국, 05030
- 모병
- Clinical Trial Site
-
-
-
-
-
Berlin, 독일, 10117
- 모병
- Clinical Trial Site
-
Heidelberg, 독일, 69120
- 모병
- Clinical Trial Site
-
Münster, 독일, 48149
- 모병
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, 말레이시아, 59100
- 모병
- Clinical Trial Site
-
-
-
-
-
Guadalajara, 멕시코, 44670
- 모병
- Clinical Trial Site
-
Tlalpan, 멕시코, 14080
- 모병
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02118
- 모병
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Clinical Trial Site
-
-
New York
-
New York, New York, 미국, 10032
- 모병
- Clinical Trial Site
-
New York, New York, 미국, 10016
- 모병
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- 모병
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- 모병
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, 미국, 75246
- 모병
- Clinical Trial Site
-
Houston, Texas, 미국, 77030
- 모병
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, 브라질, 14051-140
- 모병
- Clinical Trial Site
-
Rio de Janeiro, 브라질, 22640-100
- 모병
- Clinical Trial Site
-
Rio de Janeiro, 브라질, 22775-001
- 모병
- Clinical Trial Site
-
Salvador, 브라질, 40290-000
- 모병
- Clinical Trial Site
-
São Paulo, 브라질, 04038-002
- 모병
- Clinical Trial Site
-
-
-
-
-
Stockholm, 스웨덴, 113 61
- 모병
- Clinical Trial Site
-
Umeå, 스웨덴, 907 37
- 모병
- Clinical Trial Site
-
-
-
-
-
Bern, 스위스, 3010
- 모병
- Clinical Trial Site
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Clinical Trial Site
-
Huelva, 스페인, 21005
- 모병
- Clinical Trial Site
-
L'Hospitalet de Llobregat, 스페인, 8907
- 모병
- Clinical Trial Site
-
Madrid, 스페인, 28040
- 모병
- Clinical Trial Site
-
Palma de Mallorca, 스페인, 07198
- 모병
- Clinical Trial Site
-
-
-
-
-
Belgrano, 아르헨티나, C1428AQK
- 모병
- Clinical Trial Site
-
Rosario, 아르헨티나, CP2000
- 모병
- Clinical Trial Site
-
-
-
-
-
Dublin, 아일랜드, D24 NR0A
- 모병
- Clinical Trial Site
-
-
-
-
-
London, 영국, NW3 2QG
- 모병
- Clinical Trial Site
-
-
-
-
-
Florence, 이탈리아, 50134
- 모병
- Clinical Trial Site
-
Milan, 이탈리아, 20133
- 모병
- Clinical Trial Site
-
Padova, 이탈리아, 35128
- 모병
- Clinical Trial Site
-
Pavia, 이탈리아, 27100
- 모병
- Clinical Trial Site
-
Roma, 이탈리아, 00168
- 모병
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, 일본, 113-8519
- 모병
- Clinical Trial Site
-
Kumamoto, 일본, 860-8556
- 모병
- Clinical Trial Site
-
Matsumoto-shi, 일본, 390-8621
- 모병
- Clinical Trial Site
-
Suita, 일본, 565-0871
- 모병
- Clinical Trial Site
-
-
-
-
-
Vancouver, 캐나다, V5Z 1M9
- 모병
- Clinical Trial Site
-
-
-
-
-
Égkomi, 키프로스, 2371
- 모병
- Clinical Trial Site
-
-
-
-
-
Istanbul, 터키 (Türkiye), 34093
- 모병
- Clinical Trial Site
-
Izmir, 터키 (Türkiye), 35330
- 모병
- Clinical Trial Site
-
-
-
-
-
Lisbon, 포르투갈, 1649-035
- 모병
- Clinical Trial Site
-
Porto, 포르투갈, 4099-001
- 모병
- Clinical Trial Site
-
-
-
-
-
Créteil, 프랑스, 94000
- 모병
- Clinical Trial Site
-
Le Kremlin-Bicêtre, 프랑스, 94270
- 모병
- Clinical Trial Site
-
Marseille, 프랑스, 13005
- 모병
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, 호주, 2010
- 모병
- Clinical Trial Site
-
Woolloongabba, 호주, 4102
- 모병
- Clinical Trial Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
다른 이름들:
|
|
활성 비교기: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
다른 이름들:
Vutrisiran 25 mg administered SC q3M
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
기간: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
9개월 동안 누크레시란 군에서 인-스터디 부트리시란 군에 비한 혈청 TTR 수준의 백분율 감소
기간: 최대 9개월
|
최대 9개월
|
|
|
누크레시란 군에서 혈청 TTR 수준의 백분율 감소, 18개월 차까지 연구 중인 부트리시란 군과 비교
기간: 최대 18개월
|
최대 18개월
|
|
|
누크레시란 군의 혈청 TTR 수준 감소율과 연구 내부 부트리시란 군 간의 6주차 비교
기간: 6주차
|
6주차
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
기간: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
기간: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
기간: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
기간: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
기간: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
기간: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
기간: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Medical Director, Alnylam Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- ALN-TTRSC04-004
- 2025-522544-40-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .